Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Early Phase 1TerminatedNCT03468543

Lyndra Inc.3 enrolled

Overview

To assess how long modified release (MR) memantine hydrochloride prototype capsule formulations stay in the stomach as determined by magnetic resonance imaging (MRI).

This is a single center, open-label, single dose, 5-period study in 24 healthy male and female subjects, with an optional Period 6, if required. It is expected the study will be executed in 3 cohorts of 8 subjects, with each cohort participating in up to 2 study periods (total of up to 6 study periods). Cohort 3 may be conducted in parallel with Cohort 2. Subjects will be dosed in a sequential manner, as appropriate. Each subject will be administered up to 2 regimens (2 different prototype capsule formulations) across 2 study periods. There will be a minimum 35-day interval between each dose administration. Subjects will have an MRI scan performed on Days 2, 4, 7, 10 and 14 of each period to assess the gastric retentive properties of the formulation.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Gastric Retention Healthy

Interventions

Memantine Hydrochloride MR Prototype Capsule Formulation ADRUG

Memantine HCl MR capsule formulation will be administered orally in a single dose

Memantine Hydrochloride MR Prototype Capsule Formulation BDRUG

Memantine HCl MR capsule formulation will be administered orally in a single dose

Memantine Hydrochloride MR Prototype Capsule Formulation CDRUG

Memantine HCl MR capsule formulation will be administered orally in a single dose

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Healthy male and female subjects. 2. Body mass index of 18.0 to 32.0 kg/m2. 3. Subjects must demonstrate their ability to swallow a test capsule at screening. 4. Must provide written informed consent. Exclusion Criteria: 1. Subjects who have received any investigational medicinal product in a clinical research study within the previous 3 months. 2. Subjects who have previously been enrolled in this study. 3. History of any drug or alcohol abuse in the past 2 years. 4. Current smokers and those who have smoked within the last 12 months. 5. Individuals with clinically significant medical history relating to the gastrointestinal tract and potential for complications, thereof 6. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results. 7. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients. 8. Individuals with contraindication to MRI imaging. Other protocol defined criteria may apply.

Locations (1)

Quotient Sciences (formerly Quotient Clinical)

Ruddington, Nottingham, United Kingdom

Outcomes

Primary Outcomes

Gastric Retention by Magnetic Resonance Imaging (MRI)

Number of Participants with Gastric Retention by Magnetic Resonance Imaging (MRI), as measured after dosing

Time frame: 7 Days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.